Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.
Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.
Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.
Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.
OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.
Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.
Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
At the SPAC of Dawn While futures indicate the Santa rally may be retreating back to the North Pole, de-SPACs have nonetheless notched a solid week and SPACs still in other points in their processes still have plenty of business left on their plate. Three SPACs are asking shareholders for extensions today while two more...
SPACInsider 2024 Awards 2024 was clearly a rebuilding year for SPACs and the pace didn’t really gather momentum until June. But in typical SPAC fashion, once the market catches fire, it builds very, very quickly. With that being said, there are some noteworthy standouts this year that are worth highlighting. As such, this is the...
At the SPAC of Dawn (UPDATED) It was a slow start to the day after the Christmas holiday, especially because the SEC was “experiencing technical difficulties” this morning. That makes for a slow news day. Other than that, we hope everyone had a great holiday and is easing back into the work flow. Deals and...
Aimei Health Technology II Co., Ltd (NASDAQ:AHJKU) has filed for a $60 million SPAC ostensibly to pair up with a small cap biotech or medical device target, but its team’s experience both in SPACs and beyond suggest the vehicle will be open to a broad set of potential targets. It is the first SPAC to...
At the SPAC of Dawn The markets got to open one stocking early yesterday, but it was mostly coal as it showed durable goods orders had declined by more than twice as much as expected to -1.1% in November. It wasn’t all signs of naughtiness, however. Amid the numbers that came public one day earlier...